Editas Medicine EDIT incurred a loss of 15 cents per share in the second quarter of 2026, narrower than the Zacks Consensus Estimate of a loss of 30 cents. The company had reported a loss of 63 cents per share in the year-ago quarter.
Collaboration and other research and development revenues totaled approximately $11.9 million, comfortably surpassing the Zacks Consensus Estimate of $2 million. Revenues were $3.6 million in the year-ago quarter. The increase reflected deferred revenues recognized following the expiration of certain rights under the company’s collaboration with Bristol Myers.
EDIT’s Q2 Results in Detail
Research and development expenses increased 25% year over year to $20.2 million in the second quarter of 2026. The increase was primarily related to higher external expenses supporting ongoing research and preclinical work for EDIT-401.
General and administrative expenses declined 10% to $11.6 million from $12.9 million in the year-ago quarter. The decrease was due to lower employee-related expenses and reduced professional services costs following the workforce reduction and discontinuation of the reni-cel program.
Editas Benefits From Restructuring Adjustments
Editas recorded a restructuring and impairment benefit of $1.3 million in the reported quarter. This compared favorably with restructuring and impairment charges of $26.1 million in the second quarter of 2025.
The benefit reflected favorable adjustments to previously estimated contract costs associated with the discontinuation of the reni-cel program.
Editas had cash, cash equivalents and investments worth $211.6 million as of June 30, 2026, compared with $123.6 million as of March 31, 2026. The company expects its existing cash position to fund operating and capital needs into the second half of 2028.
Year to date, shares of Editas have soared 34.1% compared with the industry’s 2.5% growth.
Image Source: Zacks Investment Research
EDIT’s Key Pipeline Update
Editas has no approved products in its portfolio at present. Therefore, progress with its gene-editing pipeline, particularly lead candidate EDIT-401, remains the company’s primary focus.
EDIT-401 is an experimental, one-time in vivo gene-editing therapy targeting the LDLR gene. The candidate is being developed for patients with heterozygous familial hypercholesterolemia, an inherited disorder associated with elevated LDL cholesterol and increased cardiovascular risk.
Editas Reports Encouraging Preclinical Data
Editas presented new preclinical findings for EDIT-401 at several scientific conferences. A single dose of the candidate produced mean reductions of approximately 90% or more in LDL cholesterol, lipoprotein(a) and apolipoprotein B in non-human primates.
The reductions were rapid and dose-dependent. A mean LDL cholesterol reduction of at least 90% remained durable for approximately six months. The company also reported no adverse clinical observations in non-human primates receiving a single dose of 1.5 milligrams per kilogram.
EDIT Advances Toward Clinical Development
Editas remains on track to submit a Clinical Trial Notification in Australia in August 2026. The filing is intended to support the initiation of a phase I/II study evaluating EDIT-401 in patients with heterozygous familial hypercholesterolemia.
The study will assess the safety, tolerability and efficacy of a single dose of EDIT-401. Its first part will use a single ascending dose, open-label design. Editas has selected four clinical study sites across Australia and New Zealand.
The company expects to provide an EDIT-401 data update in the first quarter of 2027. It also plans to complete enrollment in the dose-finding portion of the phase I/II study and report top-line results in 2027.
Editas Medicine, Inc. Price, Consensus and EPS Surprise
Editas Medicine, Inc. price-consensus-eps-surprise-chart | Editas Medicine, Inc. Quote
EDIT’s Zacks Rank & Stocks to Consider
Editas currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Harmony Biosciences HRMY, Repligen RGEN and Liquidia Corporation LQDA, each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Harmony Biosciences’ 2026 earnings per share have risen from $3.20 to $3.33, while estimates for 2027 have increased from $3.64 to $3.87 during the same time. HRMY shares have gained 2.2% year to date.
Harmony Biosciences’ earnings missed estimates in three of the trailing four quarters and beat on the remaining occasion, delivering an average negative surprise of 13.97%.
Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.62 during the same time. RGEN shares have declined 3.2% year to date.
Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $5.31 during the same time. LQDA shares have surged 158.4% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.
7 Best Stocks for the Next 30 Days
Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."
Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.9% per year. So be sure to give these hand picked 7 your immediate attention.
See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Editas Medicine, Inc. (EDIT): Free Stock Analysis Report
Repligen Corporation (RGEN): Free Stock Analysis Report
Liquidia Corporation (LQDA): Free Stock Analysis Report
Harmony Biosciences Holdings, Inc. (HRMY): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).